FDA grants final approval for pioglitazone tablets

02/17/2013 | Pharmaceutical Business Review Online

Aurobindo Pharma received final FDA approval to market its pioglitazone tablets in 15 mg, 30 mg and 45 mg strengths and pioglitazone hydrochloride plus metformin hydrochloride tablets in 15 mg (base)/500 mg and 15 mg (base)/850 mg doses to treat type 2 diabetes.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC